Clinical Trial Update: A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) [Phase 1]

View source ↗

Summary

Phase I study of lintuzumab combined with lenalidomide in myelodysplastic syndromes has completed enrollment and status is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Lenalidomide (lenalidomide)
• Lintuzumab (lintuzumab)

Snippet

Sponsor: Seagen Inc. | Conditions: Myelodysplastic Syndrome (MDS) | Phase 1 | Status: COMPLETED